AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) is scheduled to announce its Q416 earnings results on Tuesday, February 14th. Analysts expect the company to announce earnings of $1.85 per share and revenue of $155.12 million for the quarter. Investors that wish to register for the company’s conference call can do so using this link.
Shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) opened at 23.25 on Monday. The stock’s 50 day moving average is $26.51 and its 200-day moving average is $27.14. The stock has a market cap of $795.36 million, a price-to-earnings ratio of 53.45 and a beta of 1.09. AMAG Pharmaceuticals, Inc. has a 1-year low of $17.92 and a 1-year high of $36.83.
A number of brokerages have recently weighed in on AMAG. J P Morgan Chase & Co reiterated a “hold” rating and issued a $33.00 target price on shares of AMAG Pharmaceuticals in a report on Friday, November 4th. Cantor Fitzgerald reissued a “neutral” rating and issued a $33.00 price target on shares of AMAG Pharmaceuticals in a research note on Wednesday, December 21st. Guggenheim initiated coverage on AMAG Pharmaceuticals in a research note on Monday, November 7th. They issued a “buy” rating and a $42.00 price target for the company. Leerink Swann cut AMAG Pharmaceuticals from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $39.00 to $25.00 in a research note on Tuesday, January 10th. Finally, Needham & Company LLC cut AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, January 11th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and three have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $31.80.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/amag-pharmaceuticals-inc-amag-to-release-quarterly-earnings-on-tuesday/1657276.html
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.